Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas

Cancer Research

Volumn 76, Issue 4, 2016, Pages 796-804

  Hilvo, Mika ^a   De Santiago, Ines ^b   Gopalacharyulu, Peddinti ^c   Schmitt, Wolfgang D ^d   Budczies, Jan ^d   Kuhberg, Marc ^d   Dietel, Manfred ^d   Aittokallio, Tero ^c   Markowetz, Florian ^b   Denkert, Carsten ^d   Sehouli, Jalid ^d   Frezza, Christian ^b   Darb Esfahani, Silvia ^d   Braicu, Elena Ioana ^d  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIHYDROXYBUTYRIC ACID; 3 HYDROXYISOVALERIC ACID; 3,4 DIHYDROXYBUTYRIC ACID; 4 HYDROXYPHENYLLACTIC ACID; ADIPIC ACID; CA 125 ANTIGEN; ERYTHRITOL; HYDROXYBUTYRIC ACID; SUCCINATE SEMIALDEHYDE DEHYDROGENASE; TUMOR MARKER; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR;

ALDH5A1 GENE; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLITE; METABOLOMICS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; CANCER GRADING; CYSTADENOCARCINOMA, SEROUS; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; HYDROXYBUTYRATES; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84960445849     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2298     Document Type: Article

References (43)

1. Stewart BW, Wild CP. World Cancer Report 2014. Geneva: WHO; 2014.
2. Prat J. New insights into ovarian cancer pathology. Ann Oncol 2012;23.
3. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res 2009;2:13.
4. Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, et al. Biomarkers for early detection of ovarian cancer. Womens Health (Lond Engl) 2013;9:171-85; quiz 186-7.
5. Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, et al. Early detection biomarkers for ovarian cancer. J Oncol 2012;2012:709049.
6. Sciacovelli M, Gaude E, Hilvo M, Frezza C. The metabolic alterations of cancer cells. Methods Enzymol 2014;542:1-23.
7. Ke C, Hou Y, Zhang H, Fan L, Ge T, Guo B, et al. Large-scale profiling of metabolic dysregulation in ovarian cancer. Int J Cancer 2015;136:516-26.
8. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabolomics. Int J Cancer 2005;113:782-8.
9. Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res 2011;10:1765-71.
10. Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. ["IMO"-intraoperative mapping of ovarian cancer]. Zentralbl Gynakol 2003;125:129-35.
11. Castillo S, Mattila I, Miettinen J, Oresic M, Hyotylainen T. Data analysis tool for comprehensive two-dimensional gas chromatography/time-offlight mass spectrometry. Anal Chem 2011;83:3058-67.
12. Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, Turnbaugh PJ, et al. Detecting novel associations in large data sets. Science 2011;334:1518-24.
13. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21:3940-1.
14. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
15. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
16. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genomewide validation of survival-associated biomarkers in ovariancancer using microarray data from 1287 patients. Endocr Relat Cancer 2012;19:197-208.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 2005;102:15545-50.
18. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010;107:15449-54.
19. Zhang T, Wu X, Yin M, Fan L, Zhang H, Zhao F, et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012;413:861-8.
20. FongMY,McDunn J, Kakar SS. Identification ofmetabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 2011;6:e19963.
21. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503.
22. Jakobs C, Sweetman L, Nyhan WL, Packman S. Stable isotope dilution analysis of 3-hydroxyisovaleric acid in amniotic fluid: contribution to the prenatal diagnosis of inherited disorders of leucine catabolism. J Inherit Metab Dis 1984;7:15-20.
23. Yu WM, Kuhara T, Inoue Y, Matsumoto I, Iwasaki R, Morimoto S. Increased urinary excretion of beta-hydroxyisovaleric acid in ketotic and non-ketotic type II diabetes mellitus. Clin Chim Acta 1990;188:161-8.
24. Brown GK, Cromby CH, Manning NJ, Pollitt RJ. Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: evidence of alpha-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial beta-oxidation. J Inherit Metab Dis 1987;10:367-75.
25. Shinka T, Inoue Y,Ohse M, Ito A, Ohfu M, Hirose S, et al. Rapid and sensitive detection of urinary 4-hydroxybutyric acid and its related compounds by gas chromatography-mass spectrometry in a patient with succinic semialdehyde dehydrogenase deficiency. J Chromatogr B 2002;776:57-63.
26. Pearl PL, Dorsey AM, Barrios ES, Gibson KM. Succinic semialdehyde dehydrogenase deficiency. Seattle: University of Washington; 2013.
27. Zhang GF, Sadhukhan S, Ibarra RA, Lauden SM, Chuang CY, Sushailo S, et al. Metabolism of gamma-hydroxybutyrate in perfused rat livers. Biochem J 2012;444:333-41.
28. Nicholson-Guthrie CS, Guthrie GD, Sutton GP, Baenziger JC. Urine GABA levels in ovarian cancer patients: elevated GABA in malignancy. Cancer Lett 2001;162:27-30.
29. Denkert C, Budczies J, Kind T, WeichertW, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-804.
30. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells aremaintained by activated glycolyticmetabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 2013;110:8644-9.
31. Ishiguro Y, Kajita M, Aoshima T, Watanabe K, Kimura M, Yamaguchi S. The first case of 4-hydroxybutyric aciduria in Japan. Brain Dev 2001; 23:128-30.
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
33. Aspuria PP, Lunt SY,Väremo L, Vergnes L, GozoM, Beach JA, et al. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab 2014;2:1-15.
34. Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libe R, et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab 2012;97:E954-62.
35. Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, et al. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem 2012;287:42180-94.
36. Lin C-C, Cheng T-L, Tsai W-H, Tsai H-J, Hu K-H, Chang H-C, et al. Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci Rep 2012;2:785.
37. Björkhem I, Blomstrand S, Haga P, Kase BF, Palonek E, Pedersen JI, et al. Urinary excretion of dicarboxylic acids from patients with the Zellweger syndrome. Importance of peroxisomes in beta-oxidation of dicarboxylic acids. Biochim Biophys Acta 1984;795:15-9.
38. Mayatepek E, Seppel CK, Hoffmann GF. Increased urinary excretion of dicarboxylic acids and 4-hydroxyphenyllactic acid in patients with Zellweger syndrome. Eur J Pediatr 1995;154:755-6.
39. Musa-Veloso K, Likhodii SS, Cunnane SC. Breath acetone is a reliable indicator of ketosis in adults consuming ketogenic meals. Am J Clin Nutr 2002;76:65-70.
40. Mortensen PB. Urinary excretion of C4-C10-dicarboxylic acids and antiketogenic properties of adipic acid in ketogenic-stimulated rats due to diabetes, long-chain and short-chain monocarboxylic acids. Biochim Biophys Acta 1981;664:335-48.
41. Kardon T, Stroobant V, Veiga-da-Cunha M, Schaftingen EV. Characterization ofmammalian sedoheptulokinase andmechanism of formation of erythritol in sedoheptulokinase deficiency. FEBS Lett 2008;582: 3330-4.
42. Valayannopoulos V, Verhoeven NM, Mention K, Salomons GS, Sommelet D, Gonzales M, et al. Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. J Pediatr 2006;149: 713-7.
43. Lee B, Scaglia F, eds. Inborn errors of metabolism: From neonatal screening to metabolic pathways. New York: Oxford University Press, 2014.